Anaqua Integrates Big Data Analytics into Intellectual Property Management
Anaqua, Inc., a leading provider of intellectual property analytics and management software and services, today announced the availability of a major product release that embeds big data analytics into the leading IP Management platform. ANAQUA 8.6 enriches the IP process with business insight gleaned from more than 100 million patents and 1 billion related artifacts. This intelligent system uncovers fresh opportunities to drive revenue and reduce costs and risk through unique new capabilities powered by the integration of analytics from AcclaimIP, which Anaqua acquired in the spring of 2016.
As competitive organizations seek to become smarter about getting maximum business value from intellectual property at the lowest possible cost, they need insight that guides better decisions throughout the process. Historically the power of IP analytics was tapped by a select few data analysts and search specialists. ANAQUA 8.6 is the first IP management platform to infuse the entire process of creating, protecting and monetizing IP with analytics delivered to the right user, in the right format at the right time. For the first time, inventors, business executives, IP leaders, operations managers, attorneys, and paralegals can benefit from the insight delivered through a unified IP platform.
Key features in ANAQUA 8.6 include:
- My HyperViews™ - the flexibility to create and share interactive dashboards.
- Snapshot Analytics™ - pre-packaged analytics with configurable charts and visuals included in the IP Management Platform to aggregate the patent’s score based on its lifecycle.
- Smart WorkSpaces™ - deliver analytics to every stakeholder with persona-based workspaces that bring insights, content, tools and tasks together for making strategic and more informed decisions.
- Anti-counterfeit mobile app with geo-location – photograph and report on location for potentially phony products.
- Anaqua to Anaqua – an interface that allows law firms and their clients to exchange data seamlessly and securely.
“Our customers wanted more than just a product suite so we took a different approach,” said Bob Romeo, Anaqua CEO. “Big data has game-changing potential. We put the power of insight into the hands of everyone who needs it by embedding analytics into the IP workflow. This is unique and it will help our customers make better decisions.”
“Anaqua continues to lead and innovate in their latest release with a powerful toolkit to drive IP as a business – and they score big,” said Eyal Iffergan, President of Hyperion Research, the legal industry’s leading analyst-based market research firm covering the IP solutions market. “We mean that quite literally,” continued Iffergan, “as Anaqua’s new release deftly showcases recent acquisition AcclaimIP’s proprietary Patent Score technology. Demonstrating one of the fastest platform integrations we’ve ever observed, 8.6 is loaded with Patent Score indicators, engaging HyperView visualizations, and contextual analytics tightly integrated into a robust IP operations platform. Anaqua’s pragmatic, thoughtful approach to data-driven decision support is precisely what makes IP Business Management (IPBM) approachable IP.”
About Anaqua, Inc.
Anaqua helps corporations and law firms turn intellectual property into competitive advantage. Its software platform combines insight from big data analytics with critical tools, best practice workflows and services into one efficient, intelligent environment that helps IP practices work more efficiently and make better decisions faster. Many of the best-known brands and most innovative products were conceptualized, evaluated, protected and monetized through the ANAQUA platform. Founded in 2004 by IP leaders from The Coca-Cola Company, Ford Motor Company, Kimberly-Clark and British American Tobacco, Anaqua is a privately held company headquartered in Boston (U.S.) and has locations across Europe and Asia.
For additional information, please visit http://www.anaqua.com.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom